Meeting
2021 ASCO Annual Meeting
High dimensional mapping of temporal evolution within the marrow microenvironment in response to FLT3 inhibitor therapy.
Authors
Matthew Newman
Oregon Health & Science University, Portland, OR
Matthew Newman , Sunil K. Joshi , Daniel Bottomly , Shannon McWeeney , Brian J. Druker , Evan Lind , Elie A. Traer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7020)
DOI
10.1200/JCO.2021.39.15_suppl.7020
Abstract #
7020
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Quizartinib (QUIZ) with decitabine (DAC) and venetoclax (VEN) is active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML): A phase I/II clinical trial.
First Author: Musa Yilmaz
Poster
2023 ASCO Annual Meeting
Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia.
First Author: Amir Tahmasb Fathi
Poster
2022 ASCO Genitourinary Cancers Symposium
Expanding the use of targeted therapy for urothelial bladder cancer (UBC): Non-FGFR3 receptor tyrosine kinase (RTK) gene rearrangements (ReAr) and fusions (fus).
First Author: Andrea Necchi
Poster
2018 ASCO Annual Meeting
Determining the sensitivity of primary acute myeloid leukemia (AML) samples with FLT3-ITD or FLT3-D835 mutations to FLT3 inhibitors using an ex vivo drug sensitivity screen.
First Author: Mara Rosenberg